文章：

工程化过继性T细胞疗法在乳腺癌治疗中的应用：当前进展、挑战与前景

Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential

原文发布日期：26 December 2023

DOI: 10.3390/cancers16010124

类型: Article

开放获取: 是

英文摘要：

Breast cancer remains a significant health challenge, and novel treatment approaches are critically needed. This review presents an in-depth analysis of engineered adoptive T-cell therapies (E-ACTs), an innovative frontier in cancer immunotherapy, focusing on their application in breast cancer. We explore the evolving landscape of chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapies, highlighting their potential and challenges in targeting breast cancer. The review addresses key obstacles such as target antigen selection, the complex breast cancer tumor microenvironment, and the persistence of engineered T-cells. We discuss the advances in overcoming these barriers, including strategies to enhance T-cell efficacy. Finally, our comprehensive analysis of the current clinical trials in this area provides insights into the future possibilities and directions of E-ACTs in breast cancer treatment.

摘要翻译： 

乳腺癌仍是重大的健康挑战，亟需创新治疗方案。本综述深入探讨了工程化过继性T细胞疗法（E-ACTs）这一癌症免疫治疗的前沿领域，聚焦其在乳腺癌治疗中的应用。我们系统分析了嵌合抗原受体（CAR）与T细胞受体（TCR）T细胞疗法的发展态势，重点阐述其在乳腺癌靶向治疗中的潜力与挑战。本文针对靶抗原选择、复杂的乳腺癌肿瘤微环境以及工程化T细胞持久性等关键障碍展开论述，探讨了包括增强T细胞效能策略在内的突破性进展。最后，通过对该领域现有临床试验的全面分析，展望了E-ACTs在乳腺癌治疗中的未来前景与发展方向。

原文链接：

Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential